Trending...
- Retirement Specialist Cindy Schneiderman Featured on National CNBC Broadcast of "Moving America Forward" with Tom Hegna
- Kevin Francis Design Introduces CHROMA, a Collection of Saturated Solid Color Wool Rugs
- School Dental Screening Programs Conducted in Dubai
WESTON, Fla., May 28, 2024 ~ Cantex Pharmaceuticals, Inc. has recently announced that their drug, azeliragon, will be featured in four abstracts at the 2024 ASCO Annual Meeting in Chicago. The company, which focuses on developing transformative therapies for cancer and other life-threatening medical conditions, is excited to showcase the progress of their clinical investigations at leading cancer centers.
According to Cantex's Chief Executive Officer, Stephen G. Marcus, the 2024 ASCO Annual Meeting is a crucial opportunity to meet with top oncology researchers from around the world and highlight the potential of azeliragon in treating difficult-to-treat cancers. Azeliragon is a once-a-day pill that inhibits "RAGE" (the receptor for advanced glycation end products) and has been found to be well-tolerated by patients.
More on illi News
The four abstracts featuring azeliragon at the conference include a phase I/II study assessing its safety and potential therapeutic effect in patients with metastatic pancreatic cancer who have not responded to first-line treatment (Abstract #: TPS4212). Another abstract (#TPS2096) will focus on a phase Ib/II trial investigating the combination of azeliragon with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma.
In addition, Cantex's research on using RAGE inhibition to decrease cardiotoxicity in women with early breast cancer will also be presented (Abstract #: TPS619). Lastly, a phase I/II study examining the safety and potential therapeutic effect of combining azeliragon with stereotactic radiation therapy in patients with brain metastases will also be featured (Abstract #: TPS2093).
The company hopes that these presentations will further demonstrate the potential of azeliragon as a promising treatment option for various types of cancer. With their dedication to developing transformative therapies for life-threatening conditions, Cantex Pharmaceuticals continues to make strides in the fight against cancer.
According to Cantex's Chief Executive Officer, Stephen G. Marcus, the 2024 ASCO Annual Meeting is a crucial opportunity to meet with top oncology researchers from around the world and highlight the potential of azeliragon in treating difficult-to-treat cancers. Azeliragon is a once-a-day pill that inhibits "RAGE" (the receptor for advanced glycation end products) and has been found to be well-tolerated by patients.
More on illi News
- WFS – Washer Flood Stop Introduces Automatic Overflow Protection for Laundry Rooms
- FrostGuard Introduces Innovative Inflatable Window Well Insulation System
- Chicago: Mayor Brandon Johnson Joins Resident Association of Greater Englewood to Break Ground on The Re-up at 59th And Racine
- Chicago: Mayor Brandon Johnson Breaks Ground on C.A.R.E. Manor, Bringing 44 Affordable Homes Designed for Multi-Generational Living to West Garfield Park
- Advancing High-Potential Nevada Critical Minerals Portfolio as Major Drill Program Nears Assay Results: Glenstar Minerals: Stock Symbol: GSTRF
The four abstracts featuring azeliragon at the conference include a phase I/II study assessing its safety and potential therapeutic effect in patients with metastatic pancreatic cancer who have not responded to first-line treatment (Abstract #: TPS4212). Another abstract (#TPS2096) will focus on a phase Ib/II trial investigating the combination of azeliragon with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma.
In addition, Cantex's research on using RAGE inhibition to decrease cardiotoxicity in women with early breast cancer will also be presented (Abstract #: TPS619). Lastly, a phase I/II study examining the safety and potential therapeutic effect of combining azeliragon with stereotactic radiation therapy in patients with brain metastases will also be featured (Abstract #: TPS2093).
The company hopes that these presentations will further demonstrate the potential of azeliragon as a promising treatment option for various types of cancer. With their dedication to developing transformative therapies for life-threatening conditions, Cantex Pharmaceuticals continues to make strides in the fight against cancer.
Filed Under: Business
0 Comments
Latest on illi News
- Allstream Energy Partners Announce Media Partnership with the 2026 EPC Show - The Energy Projects Conference
- STO Foundation Launching June 29, 2026 to Advance the Global Tokenization Industry
- West Virginia Leaders Announce Support for Election Integrity Network's Model Election Laws Handbook
- CCHR Condemns Behavioral Treatment After FDA's Missed Deadline to Ban Shock Device
- Naperville: Special Citywide Brush Collection Taking Place Beginning Week of June 15
- Brilliant Minds to Gather in Fort Worth for National Mensa Event
- UK Financial Ltd Completes One Of The Most Extensive CoinMarketCap Supply Verification Packages For Maya Preferred PRA (MPRA)
- Data Tiles Strengthens U.S. Presence with Chief Revenue Officer John Goode
- Haven Media Solutions Offers Web Design and PPC Services in Atlanta GA
- Actress Zaria Imani Primer Marks Final Season of The Chi with Full-Circle Moment
- A Seat for Everyone: Naperville Comes Together
- TREND Network Announces Miami Based Reality Series "Coming Up Miami" Premiering July 1
- Beemok Hospitality Collection And KLH Group Announce Preferred Partnership
- Inkdnylon Expands Wholesale Brand Customization Program for Branded Apparel, Company Stores, and Promotional Products
- Expanding Access to Mental Health Care in Toronto with Dr. Stephen Shainbart
- Dr. Stephen Shainbart Launches Expanded Mental Health Support for Anxiety and Depression in Toronto
- Equipment Leases, Inc. Launches Updated Family Office Equipment Financing Page
- The $5 Million Man Still Begging: Incumbent Jimmy Panetta Hits Up Voters for More Cash Despite Massive War Chest
- Kevin Francis Design Introduces CHROMA, a Collection of Saturated Solid Color Wool Rugs
- Hardwood Floor Refinishing Services That Transform Spaces and Restore Lasting Beauty